Yongheng Chen

44PUBLICATIONS
45CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsMolecular targetsBiologically active moleculesMedical molecular engineering of nucleic acids and proteinsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jun 08, 2026
Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core.

|Apr 23, 2026
FOXC2 represses NFAT1-dependent transcription through a DNA-facilitated protein-protein interaction.

|Feb 06, 2026
Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.

Wenjian Zhu, Xiaojuan Chen, Xiaofei Li

|Jan 06, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Shuang Xiang, Xiaojuan Chen, Jieying Lin

|Nov 18, 2025
A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization.

Yuxin Fu, Longying Jiang, Guojian Xie

|Sep 08, 2025
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance.

Wuqing Deng, Xiaojuan Chen, Ling Yan

Pageof 8

Frequent Collaborators

10 joint publications

Xiaoyun Lu

8 joint publications

Hudie Wei

5 joint publications

Yang Zhou

5 joint publications

Longying Jiang